On March 9-10, 2026, NPR and OPB reported rolling shortages and delays of hormone replacement therapy (HRT) products at pharmacies across the United States, driven by a demand surge following the FDA's November 2025 decision to remove broad black box warnings from menopausal HRT products. The warnings, imposed after the 2002 Women's Health Initiative study, had covered cardiovascular disease, breast cancer, and probable dementia risks for over two decades.

Why It Matters

The HRT shortage sits at the intersection of three major trends reshaping sexual wellness: menopause destigmatization, telehealth expansion, and the femtech boom. Menopause products are a breakout category for 2026, and companies like Elektra Health, Evernow, Gennev, and Joylux stand to benefit as women seek alternatives to pharmacy shortages through digital-first platforms. The removal of black box warnings effectively unlocks decades of pent-up demand from women and clinicians who were deterred by overstated risk messaging — demand the supply chain wasn't prepared to absorb.

The shortage is hitting transdermal estradiol patches hardest, as updated research shows patches bypass the liver and carry lower blood clot risks compared to the oral estrogen pills used in the original WHI study. Amneal Pharmaceuticals, a major estradiol patch manufacturer, confirmed to NPR a "significant increase in demand" since the FDA action. The American Society of Health-System Pharmacists lists multiple estrogen products with current or recent shortages. CVS has confirmed supply issues to reporters.

Dr. Nora Lansen, Chief Medical Officer of menopause telehealth platform Elektra Health, noted that demand has been building for four to five years as clinicians familiarize themselves with current research showing HRT's benefits when initiated within 10 years of menopause onset: an associated 50% reduction in heart attack risk, 64% reduction in cognitive decline, and 35% lower Alzheimer's risk. Patient Jennifer Skoog Mondesir of Jersey City described the situation as "a monthly mad scramble" to find patches at CVS, eventually switching to an online pharmacy to avoid disruptions.

The first batch of products with updated labeling — including Prometrium, Divigel, Cenestin, Enjuvia, Estring, and Bijuva — became available in February 2026, and the endometrial cancer warning remains for estrogen-alone products.

Sources

Update — 2026-03-28

Initial entry — story first created.